AtriCure Inc. (NASDAQ:ATRC) stock has reached a new 52-week high, touching the $39.08 mark and signaling a robust performance that has caught the attention of investors. The medical device company, valued at $1.9 billion, has demonstrated impressive momentum with a 50% surge over the past six months, according to InvestingPro data. This milestone reflects a significant uptrend for the medical device company, which specializes in developing treatments for atrial fibrillation and related conditions. The company's robust 17.6% revenue growth and impressive 74.8% gross margin highlight its operational strength. With a "GOOD" Financial Health score from InvestingPro, and strong analyst recommendations, AtriCure continues to demonstrate solid business fundamentals. The achievement of this 52-week high represents a key indicator of investor confidence and market momentum for AtriCure's shares. For deeper insights, investors can access comprehensive analysis through InvestingPro's detailed research reports, available for over 1,400 US stocks including ATRC.
In other recent news, AtriCure Inc. has reported a year-over-year increase of 17% in its fourth-quarter 2024 revenue, surpassing market expectations with a total of $124.3 million. The medical device company's U.S. revenue for the quarter is projected to reach $101.6 million, a 14% growth year-over-year. International sales also demonstrated strong performance, expecting to hit $22.7 million, a significant 28% growth from the previous year. Needham has reiterated its Buy rating on AtriCure's shares, highlighting these recent developments.
For the full year of 2024, AtriCure anticipates revenue to reach $465.3 million, slightly above the consensus estimate. The company's adjusted EBITDA is expected to be in the range of approximately $26-29 million, in line with the consensus, and adjusted earnings per share (EPS) to be between ($0.74) and ($0.80), which is more favorable than the consensus estimate.
Looking ahead, AtriCure provided guidance for 2025, projecting revenue to be in the range of approximately $517-527 million, which represents an 11-13% growth. The company's adjusted EBITDA for 2025 is expected to be between $40-44 million, surpassing the consensus. Piper Sandler analysts expressed optimism for AtriCure's future, anticipating positive fiscal year outlooks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.